Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study

被引：1
|
作者：
Villegas, Ana [1 ]
Arrizabalaga, B. [2 ]
Fernandez-lago, C. [3 ]
Mouzo, M. [4 ]
Mayans, Jr [5 ]
Gonalez-Porras, Jr [6 ]
Duarte, Rafael [7 ]
Remacha, Angel Francisco [8 ]
Luno, Elisa [9 ]
Gasquet, J. A.
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] Hosp Cruces, Dept Haematol, Bilbao, Spain
[3] Hosp Juan Canalejo, Dept Haematol, La Coruna, Spain
[4] Complejo HU Vigo Xeral Cies, Dept Haematol, Vigo, Spain
[5] Hosp Arnau Vilanova, Dept Haematol, Valencia, Spain
[6] Hosp Univ Salamanca, Salamanca, Spain
[7] Hosp Duran & Reynals ICO, Bellvitge, Spain
[8] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[9] Hosp Univ Cent Asturias, Oviedo, Spain
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
10.1182/blood.V112.11.3451.3451
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1184 / 1184
页数：1
相关论文
共 50 条
  • [1] Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response
    Villegas, A.
    Arrizabalaga, B.
    Fernandez-Lago, C.
    Castro, M.
    Mayans, J. R.
    Gonzalez-Porras, J. R.
    Duarte, R. F.
    Remacha, A. F.
    Luno, E.
    Gasquet, J. A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 951 - 960
  • [2] A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Harada, Hironori
    Shibayama, Hirohiko
    Jang, Jun Ho
    Shimazaki, Ryutaro
    Mitani, Kinuko
    Sawada, Kenichi
    Kim, Hyeoung-Joon
    BLOOD, 2014, 124 (21)
  • [3] Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
    Stasi, R
    Abruzzese, E
    Lanzetta, G
    Terzoli, E
    Amadori, S
    ANNALS OF ONCOLOGY, 2005, 16 (12) : 1921 - 1927
  • [4] An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Goede, Jeroen Simon
    Guerci-Bresler, Agnes
    Delforge, Michel
    Oliva, Esther Natalie
    Mayer, Jiri
    Badre, Sejal
    Mehta, Bhakti
    Brandao, Cisio De Oliveira
    BLOOD, 2017, 130
  • [5] EFFECT OF ERYTROPOIETIN-ALFA AND DARBEPOETIN ALFA IN LOW AND INTERMEDIATE 1 RISK MYELODYSPLASTIC SYNDROMES WITH ANEMIA: ONE CENTER EXPERIENCE
    Aslaner, M.
    Erol, B.
    Topal, B.
    Ilikhan, S. Uygun
    Ertop, S.
    LEUKEMIA RESEARCH, 2016, 49 : S45 - S45
  • [6] ARCADE (20090160): A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN THE TREATMENT OF ANEMIA IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J. S.
    Delforge, M.
    Mayer, J.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    HAEMATOLOGICA, 2016, 101 : 15 - 15
  • [7] A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Oliva, Esther N.
    Goede, Jeroen S.
    Delforge, Michel
    Mayer, Jiri
    Slama, Borhane
    Badre, Sejal
    Gasal, Eduard
    Mehta, Bhakti
    Franklin, Janet
    BLOOD, 2016, 128 (22)
  • [8] Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload
    Du, Yali
    Long, Zhangbiao
    Chen, Miao
    Han, Bing
    Hou, Bo
    Feng, Feng
    ACTA HAEMATOLOGICA, 2017, 138 (02) : 119 - 128
  • [9] Darbepoetin α for the treatment of anemia in patients with myelodysplastic syndromes
    Giraldo, Pilar
    Nomdedeu, Benet
    Loscertales, Javier
    Requena, Carmen
    de Paz, Raquel
    Tormo, Mar
    Navarro, Pilar
    Benedit, Patricia
    Gasquet, Jose Antonio
    CANCER, 2006, 107 (12) : 2807 - 2816
  • [10] A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes
    Jun Ho Jang
    Hironori Harada
    Hirohiko Shibayama
    Ryutaro Shimazaki
    Hyeoung-Joon Kim
    Kenichi Sawada
    Kinuko Mitani
    International Journal of Hematology, 2015, 102 : 401 - 412
12345